# EDGAR Filing Document

**Accession Number:** 0001410098
**File Stem:** 0001213900-25-110086
**Filing Date:** 2025-11
**Character Count:** 21407
**Document Hash:** 87875d90210dd19ab6dfe1a451526d47
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-110086.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001213900-25-110086

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**EFFECTIVENESS DATE**: 20251113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CorMedix Inc.
- **CENTRAL INDEX KEY:** 0001410098
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291512
- **FILM NUMBER:** 251479482

**BUSINESS ADDRESS:**
- **STREET 1:** 300 CONNELL DRIVE
- **STREET 2:** SUITE 4200
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922
- **BUSINESS PHONE:** 908-517-9500

**MAIL ADDRESS:**
- **STREET 1:** 300 CONNELL DRIVE
- **STREET 2:** SUITE 4200
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922

**As filed with the Securities and Exchange Commission on November 13, 2025**

**Registration Statement No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**CORMEDIX INC.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**20-5894890** |
| &nbsp;&nbsp; **(State of other jurisdiction of**<br> **incorporation or organization)** | &nbsp;&nbsp; **(I.R.S. Employer**<br> **Identification No.)** |

---

**CorMedix Inc.**

**300 Connell Drive, Suite 4200**

**Berkeley Heights, NJ 07922**

(Address of principal executive offices) (Zip code)

**Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan**

(Full title of the plan)

**Joseph Todisco**

**Chief Executive Officer**

**CorMedix Inc.**

**300 Connell Drive, Suite 4200**

**Berkeley Heights, New Jersey 07922**

**Telephone: (908) 517-9500**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

*Copies to*:

**Jared Fertman** 

**Andrew Marmer**

**Willkie Farr and Gallagher LLP**

**787 Seventh Ave**

**New York, New York 10019**

**Telephone: (212) 728-8000**

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Act. (Check one):

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

This Registration Statement relates to the registration of an additional 7,672,000 shares of common stock, $0.001 par value per share ("Common Stock"), of CorMedix Inc. (the "Registrant"), for issuance under the Amended and Restated CorMedix Inc 2019 Omnibus Stock Incentive Plan (the "Plan"). The shares of Common Stock are securities of the same class and related to the same employee benefit plan, the Plan, as amended and restated on October 13, 2022, as those registered pursuant to the Registrant's registration statement on Form S-8, previously filed with the Securities and Exchange Commission (the "Commission") on November 9, 2010, December 13, 2013, August 7, 2016, December 17, 2019 and October 26, 2022.

The Board of Directors of the Registrant approved an amendment to the Plan on September 17, 2024 and October 7, 2024 and the Registrant's stockholders approved the amendment at the Registrant's 2024 Annual Meeting of Stockholders on November 21, 2024 ("Amendment No. 1"). The Board of Directors of the Registrant approved a second amendment to the Plan on September 14, 2025 and the Registrant's stockholders approved the amendment at the Registrant's Special Meeting of Stockholders on November 10, 2025 ("Amendment No. 2" and, together with Amendment No. 1, the "Amendments"). The Amendments increased the number of shares of Common Stock reserved and available for issuance under the Plan by the number of shares being registered herein.

In accordance with General Instruction E of Form S-8, the contents of the Registrant's registration statements on Form S-8 (file numbers 333-170498, 333-192840, 333-212430, 333-235556 and 333-268019) filed with the Commission on November 9, 2010, December 13, 2013, August 7, 2016, December 17, 2019 and October 26, 2022, respectively, are incorporated herein by reference and the information required by Part II is omitted, except as supplemented by the information set forth below.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

**Item 1. Plan Information.**

The information required by Item 1 is included in documents sent or given by the Registrant to participants in the plan covered by the registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act") and the introductory note to Part I of Form S-8.

**Item 2. Registrant Information and Employee Plan Annual Information.**

The written statement required by Item 2 is included in documents sent or given by the Registrant in the plan covered by this Registration Statement pursuant to Rule 428(b)(1) of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents previously filed by the Registrant with the Commission are hereby incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/1410098/000101376225001852/ea0234537-10k_cormedix.htm) for the fiscal year ended December 31, 2024 (filed with
the Commission on March 25, 2025);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Registrant 's Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025,
June 30, 2025 and September 30, 2025 (filed with the Commission on [May 6, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025039908/ea0239390-10q_cormedix.htm) , [August 7, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025072843/ea0250361-10q_cormedix.htm) and [November 12, 2025](https://www.sec.gov/Archives/edgar/data/1410098/000121390025108777/ea0264325-10q_cormedix.htm) , respectively); 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The Registrant 's Current Reports on Form 8-K filed with the Commission on [January 7, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025001392/ea0226957-8k_cormedix.htm) , [March 25, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000101376225001844/ea0235520-8k_cormedix.htm) , [April 8, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025029629/ea023738701-8k_cormedix.htm) , [April 22, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025034219/ea0238857-8k_cormedix.htm) , [May 6, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025039903/ea0240827-8k_cormedix.htm) , [June 23, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025056415/ea0246261-8k_cormedix.htm) , [June 25, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025057451/ea0246716-8k_cormedix.htm) , [June 30, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025059702/ea0247458-8k_cormedix.htm) , [August 7, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/ea0252043-8k_cormedix.htm) , [August 12, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025075010/ea0252859-8k_cormedix.htm) , [September 2, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025082956/ea0255371-8k_cormedix.htm) (as amended on [September 30, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025093983/ea0258874-8ka1_cormedix.htm)), [October 20, 2025](http://www.sec.gov/Archives/edgar/data/1410098/000121390025100156/ea0261760-8k_cormedix.htm) and [November 12, 2025](https://www.sec.gov/Archives/edgar/data/1410098/000121390025108716/ea0265136-8k_cormedix.htm) ; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) The description of the Registrant's
 common stock, par value $0.001 per share contained in the Registrant's Registration
 Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1410098/000121390021005981/ea134329-8a12b_cormedix.htm) , dated and filed with the Commission on February 2, 2021, as updated
 by [Exhibit 4.5](http://www.sec.gov/Archives/edgar/data/1410098/000121390020006521/f10k2019ex4-5_cormed.htm) to our [Form 10-K](http://www.sec.gov/Archives/edgar/data/1410098/000121390020006521/f10k2019_cormedixinc.htm) for the fiscal year ended December 31, 2019, and including
 any amendments or reports filed with the Commission for the purpose of updating such description.

To the extent that any information contained in any Current Report on Form 8-K, or any exhibit thereto, was furnished to, rather than filed with, the Commission, such information or exhibit is specifically not incorporated by reference.

All reports and other documents that the Registrant subsequently files with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that the Registrant has sold all of the securities offered under this Registration Statement or deregisters the distribution of all such securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date that the Registrant files such report or document.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8. Exhibits.**

The Exhibits to this Registration Statement are listed in the Index to Exhibits and are incorporated herein by reference.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 5.1\* | [Opinion of Willkie Farr & Gallagher LLP](ea026489101ex5-1_cormedix.htm) |
| 23.1\* | [Consent of Willkie Farr & Gallagher LLP (included as part of Exhibit 5.1)](ea026489101ex5-1_cormedix.htm) |
| 23.2\* | [Consent of Marcum LLP, Independent Registered Accounting Firm of CorMedix, Inc.](ea026489101ex23-2_cormedix.htm) |
| 23.3\* | [Consent of EisnerAmper LLP, Independent Registered Accounting Firm of Melinta Therapeutics, LLC](ea026489101ex23-3_cormedix.htm) |
| 24.1\* | [Power of Attorney (included on the signature page of this Registration Statement)](#a_001) |
| 99.1 | [Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the Form S-8 filed with the Commission on October 26, 2022)](http://www.sec.gov/Archives/edgar/data/1410098/000121390022066518/ea167579ex99-1_cormedix.htm) |
| 99.2 | [Amendment No. 1 to the Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan (Incorporated by reference to Appendix A to CorMedix Inc.'s Proxy Statement on Schedule 14A dated October 8, 2024. See SEC File Number 001-34673)](http://www.sec.gov/Archives/edgar/data/1410098/000121390024086301/ea0216921-01.htm) |
| 99.3 | [Amendment No. 2 to the CorMedix Inc. Amended & Restated 2019 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Form 10-Q filed with the Commission on November 12, 2025).](https://www.sec.gov/Archives/edgar/data/1410098/000121390025108777/ea026432501ex10-5_cormedix.htm) |
| 107\* | [Calculation of Filing Fee Table](ea026489101ex-fee_cormedix.htm) |

---

\* Filed herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Berkeley Heights, State of New Jersey, on the 13 day of November 2025.

---

| | |
|:---|:---|
| **CORMEDIX INC.** | **CORMEDIX INC.** |
| By: | /s/ Joseph Todisco |
|  | Joseph Todisco |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Joseph Todisco and Susan Blum, or each of them singly, with fully power to act without the other, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Joseph Todisco | Director and Chief Executive Officer<br> (Principal Executive Officer) | November 13, 2025 |
| Joseph Todisco |  |  |
| /s/ Susan Blum | Chief Financial Officer <br> (Principal Financial Officer and <br> Principal Accounting Officer) | November 13, 2025 |
| Susan Blum |  |  |
| /s/ Myron Kaplan | Director and Chairman of the Board | November 13, 2025 |
| Myron Kaplan |  |  |
| /s/ Janet Dillione | Director | November 13, 2025 |
| Janet Dillione |  |  |
| /s/ Gregory Duncan | Director | November 13, 2025 |
| Gregory Duncan |  |  |
| /s/ Alan W. Dunton | Director | November 13, 2025 |
| Alan W. Dunton |  |  |
| /s/ Steven Lefkowitz | Director | November 13, 2025 |
| Steven Lefkowitz |  |  |
| /s/ Robert Stewart | Director | November 13, 2025 |
| Robert Stewart |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](ex5-1_001.jpg) |  |
|  | 787 Seventh Avenue |
|  | New York, NY 10019-6099 |
|  | Tel: 212 728 8000 |
|  | Fax: 212 728 8111 |

---

November 13, 2025

CorMedix Inc.

300 Connell Drive, Suite 4200

Berkeley Heights, NJ 07922

Re: CorMedix Inc. <br> <u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

We have acted as counsel to CorMedix Inc., a Delaware corporation (the "<u>Company</u>"), with respect to the Company's Registration Statement on Form S-8 (the "<u>Registration Statement</u>") to be filed by the Company with the Securities and Exchange Commission on or about the date hereof. The Registration Statement relates to the registration under the Securities Act of 1933, as amended (the "<u>Act</u>"), by the Company of 7,672,000 shares of common stock of the Company, par value $0.001 per share (the "<u>Common Stock</u>"), reserved for issuance pursuant to the Company's Amended and Restated CorMedix Inc 2019 Omnibus Stock Incentive Plan (the "<u>Plan</u>").

We have examined, among other things, originals and/or copies (certified or otherwise identified to our satisfaction) of such documents, papers, statutes, and authorities as we have deemed necessary to form a basis for the opinion hereinafter expressed. In our examination, we have assumed the genuineness of all signatures and the conformity to original documents of all copies submitted to us. As to various questions of fact material to our opinion, we have relied without independent check or verification upon statements and certificates of officers and representatives of the Company.

Based on the foregoing, and subject to the limitations set forth below, we are of the opinion that, when the Registration Statement becomes effective under the Act, the Common Stock to be issued by the Company under the Plan, when duly issued and delivered pursuant to the terms of the Plan, will be validly issued, fully paid, and non-assessable.

This opinion is limited to the General Corporation Law of the State of Delaware, and we express no opinion with respect to the laws of any other jurisdiction or any other laws of the State of Delaware. This opinion speaks only as of the date hereof and is limited to present statutes, regulations and administrative and judicial interpretations. We undertake no responsibility to update or supplement this opinion after the date hereof.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act and any rules and regulations promulgated thereunder.

Very truly yours,<br>/s/ Willkie Farr & Gallagher LLP

Brussels Chicago Dallas Frankfurt Hamburg Houston London Los Angeles

Milan Munich New York Palo Alto Paris Rome San Francisco Washington

## Exhibit 23.2

**Exhibit 23.2**

**INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 25, 2025 relating to the financial statements appearing in the Annual Report on Form 10-K of CorMedix, Inc for the year ended December 31, 2024.

/s/ Marcum llp

Morristown, New Jersey

November 13, 2025

## Exhibit 23.3

**Exhibit 23.3**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the Registration Statement of CorMedix Inc. on Form S-8 to be filed on or about November 13, 2025, of our report dated May 12, 2025, on our audits of the financial statements of Melinta Therapeutics, LLC and Subsidiaries as of December 31, 2024 and 2023 and for each of the years then ended.

*/s/ EisnerAmper LLP*

EISNERAMPER LLP

Iselin, New Jersey

November 13, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**CorMedix Inc.**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common stock, par value $0.001 per share | (1) | Other | 7672000 | $10.72 | $82243840.00 | 0.0001381 | $11358.00 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $82243840.00 |  | 11358.00 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $11358.00 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), the Registration Statement on Form S-8 to which this exhibit relates shall be deemed to cover an indeterminate amount of additional shares of the registrant's common stock, par value $0.001 per share (the "Common Stock"), that may be offered and issued pursuant to the registrant's Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan, as amended (the "Plan") as a result of any share split, share dividend, recapitalization or similar transactions affecting the Common Stock. Calculated pursuant to Rules 457(c) and 457(h) under the Securities Act solely for the purpose of calculating the registration fee. The registration fee is calculated based on a price of $10.72 per share, which is the average of the high and low prices of the Common Stock as reported on the Nasdaq Capital Market on November 7, 2025. Represents the additional 3,360,000 and 4,312,000 shares of Common Stock reserved and available for issuance under the Plan on November 21, 2024 and November 6, 2025, respectively.